USANA Health Sciences, Inc.
USNA · NYSE
12/28/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.48 | -2.16 | -0.39 | -9.37 |
| FCF Yield | 7.48% | 5.44% | 9.13% | 5.32% |
| EV / EBITDA | 5.44 | 5.80 | 5.70 | 9.36 |
| Quality | ||||
| ROIC | 5.73% | 11.10% | 14.73% | 26.95% |
| Gross Margin | 81.13% | 80.82% | 80.58% | 81.63% |
| Cash Conversion Ratio | 1.45 | 1.11 | 1.50 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.06% | -8.10% | -4.17% | 3.80% |
| Free Cash Flow Growth | -9.31% | -39.95% | -13.79% | -25.36% |
| Safety | ||||
| Net Debt / EBITDA | -1.44 | -2.58 | -2.16 | -1.21 |
| Interest Coverage | 236.03 | 355.23 | 560.49 | 2,985.82 |
| Efficiency | ||||
| Inventory Turnover | 2.31 | 2.88 | 2.89 | 2.22 |
| Cash Conversion Cycle | 134.27 | 109.00 | 108.13 | 144.27 |